Literature DB >> 19424597

Expression of angiotensin-converting enzyme 2 in CCL4-induced rat liver fibrosis.

Qian Huang1, Qing Xie, Cui-Cui Shi, Xiao-Gang Xiang, Lan-Yi Lin, Bang-Dong Gong, Gang-De Zhao, Hui Wang, Ni-Na Jia.   

Abstract

The renin angiotensin system (RAS) plays a major role in liver fibrosis. A novel homologue of angiotensin converting enzyme, ACE2, was identified as a negative regulator of RAS as it degrades Ang II to Ang1-7. We investigated in vivo the expression of ACE2 in liver fibrosis. We evaluated the relationship between biochemical variables and liver tissue expression of ACE2, the correlation between a histological assessment of liver fibrosis and liver tissue expression of ACE2. Male SD rats were randomly divided into a CCL4 group which received injections of CCL4 and the control group which received injections of olive oil. Liver pathology was examined by H&E and Sirius red staining, and real-time PCR was performed to determine the gene expression levels of ACE2 and ACE. Real-time PCR analysis revealed that ACE2 mRNA was higher at the two-, four-, and six-week time points, respectively (p<0.01). Similarly, hepatic ACE mRNA was significantly increased after CCL4 injection. There was a significant correlation between ACE and ACE2 gene expression (r=0.750, P<0.001). ACE2 gene expression strongly correlated with ALT (r=0.669, P<0.0001) and AST levels (r=0.815, P<0.0001). There was a significant correlation between circulating ACE2 and histological scores of liver fibrosis. ACE2 and ACE gene expression correlated with the ISHAK score (r=0.850, P<0.001; r=0.806, P<0.001). There was a significant relationship between ACE2 gene expression and the degree of liver fibrosis. ACE2 plays a crucial role in liver fibrogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424597     DOI: 10.3892/ijmm_00000185

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  12 in total

Review 1.  The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function.

Authors:  Carlos M Ferrario; Jasmina Varagic
Journal:  Am J Physiol Renal Physiol       Date:  2010-04-07

2.  Effects of Yinchenhao decoction on self-regulation of renin-angiotensin system by targeting angiotensin converting enzyme 2 in bile duct-ligated rat liver.

Authors:  Lin Wu; Pi-Qi Zhou; Ji-Wen Xie; Rui Zhu; Sun-Chang Zhou; Geng Wang; Zhong-Xu Wu; Sha Hao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

Review 3.  Renin angiotensin system in liver diseases: Friend or foe?

Authors:  Ana Cristina Simões E Silva; Aline S Miranda; Natália P Rocha; Antônio L Teixeira
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

4.  Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA.

Authors:  Eva Schrom; Maja Huber; Manish Aneja; Christian Dohmen; Daniela Emrich; Johannes Geiger; Günther Hasenpusch; Annika Herrmann-Janson; Verena Kretzschmann; Olga Mykhailyk; Tamara Pasewald; Prajakta Oak; Anne Hilgendorff; Dirk Wohlleber; Heinz-Gerd Hoymann; Dirk Schaudien; Christian Plank; Carsten Rudolph; Rebekka Kubisch-Dohmen
Journal:  Mol Ther Nucleic Acids       Date:  2017-04-13

5.  Loss of angiotensin converting enzyme II (ACE2) accelerates the development of liver injury induced by thioacetamide.

Authors:  Hsi-Tien Wu; Ya-Wen Chuang; Cheng-Pu Huang; Ming-Huang Chang
Journal:  Exp Anim       Date:  2017-08-25

6.  Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system.

Authors:  Mao-Meng Tiao; Yu-Ju Lin; Hong-Ren Yu; Jiunn-Ming Sheen; I-Chun Lin; Yun-Ju Lai; You-Lin Tain; Li-Tung Huang; Ching-Chou Tsai
Journal:  Lipids Health Dis       Date:  2018-07-28       Impact factor: 3.876

7.  Up-regulation of components of the renin-angiotensin system in liver fibrosis in the rat induced by CCL₄.

Authors:  Wei Zhang; Jinfeng Miao; Pengfei Li; Yanxia Wang; Yuanshu Zhang
Journal:  Res Vet Sci       Date:  2013-02-21       Impact factor: 2.534

Review 8.  COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management.

Authors:  Penghui Li; Ying Liu; Ziqi Cheng; Xiaorui Yu; Yinxiong Li
Journal:  Biomed Pharmacother       Date:  2022-08-17       Impact factor: 7.419

Review 9.  Liver injury in COVID-19: Detection, pathogenesis, and treatment.

Authors:  Yue Cai; Li-Ping Ye; Ya-Qi Song; Xin-Li Mao; Li Wang; Yan-Zhi Jiang; Wei-Tao Que; Shao-Wei Li
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

Review 10.  Pathophysiological mechanisms of liver injury in COVID-19.

Authors:  Alexander D Nardo; Mathias Schneeweiss-Gleixner; May Bakail; Emmanuel D Dixon; Sigurd F Lax; Michael Trauner
Journal:  Liver Int       Date:  2020-11-29       Impact factor: 8.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.